Kyverna Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2023 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Kyverna Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2023 to Q4 2024.
  • Kyverna Therapeutics, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$41M, a 92% decline year-over-year.
  • Kyverna Therapeutics, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$143M, a 129% decline year-over-year.
  • Kyverna Therapeutics, Inc. annual Operating Income (Loss) for 2024 was -$143M, a 129% decline from 2023.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 -$143M -$41M -$19.7M -92% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-27
Q3 2024 -$123M -$38.8M -$22.5M -138% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 -$100M -$33.4M -$20.1M -151% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 -$80.3M -$29.4M -$17.9M -157% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$62.4M -$21.4M Oct 1, 2023 Dec 31, 2023 10-K 2025-03-27
Q3 2023 -$16.3M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$13.3M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 -$11.4M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.